Detailed Information
Cited 28 time in 
Cited 0 time in 
Cited 0 time in
Metadata Downloads
Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.
- Authors
- Choueiri, TK[Choueiri, Toni K.]; Tomczak, P[Tomczak, Piotr]; Park, SH[Park, Se Hoon]; Venugopal, B[Venugopal, Balaji]; Ferguson, T[Ferguson, Tom]; Chang, YH[Chang, Yen-Hwa]; Hajek, J[Hajek, Jaroslav]; Symeonides, SN[Symeonides, Stefan N.]; Lee, JL[Lee, Jae-Lyun]; Sarwar, N[Sarwar, Naveed]; Thiery-Vuillemin, A[Thiery-Vuillemin, Antoine]; Gross-Goupil, M[Gross-Goupil, Marine]; Mahave, M[Mahave, Mauricio]; Haas, NB[Haas, Naomi B.]; Sawrycki, P[Sawrycki, Piotr]; Zhang, E[Zhang, Eric (Pingye)]; Rogerio, JW[Rogerio, Jaqueline Willemann]; Imai, K[Imai, Kentaro]; Quinn, DI[Quinn, David I.]; Powles, T[Powles, Thomas]
- Issue Date
- 20-Jun-2021
- Publisher
- LIPPINCOTT WILLIAMS & WILKINS
- Citation
- JOURNAL OF CLINICAL ONCOLOGY, v.39, no.18
- Indexed
- SCIE
SCOPUS
- Journal Title
- JOURNAL OF CLINICAL ONCOLOGY
- Volume
- 39
- Number
- 18
- ISSN
- 0732-183X
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.